Benchmark Issues Pessimistic Forecast for Harvard Bioscience (NASDAQ:HBIO) Stock Price

Harvard Bioscience (NASDAQ:HBIO) had its target price reduced by stock analysts at Benchmark from $2.00 to $0.60 in a research report issued on Friday, MarketBeat reports. The brokerage presently has a “speculative buy” rating on the medical instruments supplier’s stock. Benchmark’s target price indicates a potential upside of 26.72% from the company’s current price.

Several other analysts have also issued reports on HBIO. Zacks Research upgraded shares of Harvard Bioscience to a “hold” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $0.60.

Harvard Bioscience Stock Down 4.1%

Shares of HBIO stock opened at $0.47 on Friday. Harvard Bioscience has a 12 month low of $0.28 and a 12 month high of $0.95. The firm has a market cap of $2.12 million, a PE ratio of -0.37 and a beta of 1.51. The stock has a 50 day moving average of $0.57 and a 200-day moving average of $0.57.

Shares of Harvard Bioscience are set to reverse split on Monday, March 16th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, March 15th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of HBIO. AMH Equity Ltd boosted its holdings in shares of Harvard Bioscience by 15.4% in the 3rd quarter. AMH Equity Ltd now owns 4,047,535 shares of the medical instruments supplier’s stock worth $1,775,000 after acquiring an additional 538,832 shares in the last quarter. Weber Capital Management LLC ADV bought a new stake in Harvard Bioscience during the 4th quarter worth approximately $2,140,000. Meros Investment Management LP increased its holdings in Harvard Bioscience by 32.6% during the 4th quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier’s stock valued at $814,000 after purchasing an additional 299,369 shares in the last quarter. Corsair Capital Management L.P. increased its holdings in Harvard Bioscience by 1,008.7% during the 4th quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock valued at $741,000 after purchasing an additional 1,008,692 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Harvard Bioscience by 7.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock valued at $606,000 after purchasing an additional 78,276 shares during the last quarter. Institutional investors own 80.87% of the company’s stock.

Key Harvard Bioscience News

Here are the key news stories impacting Harvard Bioscience this week:

• Positive Sentiment: High margins and margin-first guidance — Q4 gross margin was ~59.7% and management emphasized a high‑margin focus and structural improvements for 2026, which supports higher long‑term profitability if execution continues. GlobeNewswire: Q4 results
• Positive Sentiment: Revenue beat and modest growth outlook — Q4 revenue ($23.7M) slightly exceeded consensus and the company issued 2026 revenue guidance calling for ~2%–4% growth driven by new products for translational science, indicating gradual recovery potential. Seeking Alpha: 2026 guidance
• Positive Sentiment: C-suite stability — Interim CFO Mark Frost was appointed permanent CFO, reducing near‑term leadership uncertainty. GlobeNewswire: CFO appointment
• Neutral Sentiment: Reverse split scheduled — A 1-for-10 reverse split will take effect March 16th; this addresses low per‑share price and listing considerations but does not change the company’s fundamentals. American Banking News: Reverse split
• Negative Sentiment: EPS miss and weak profitability metrics — Q4 EPS was ($0.01) vs. a $0.04 estimate; the company reported a negative net margin (~-61.6%) and negative ROE, which helps explain selling pressure despite the revenue beat. MarketBeat: Earnings details
• Negative Sentiment: Analyst price‑target cut — Benchmark lowered its PT from $2.00 to $0.60 (but kept a “speculative buy” stance), reducing visible upside from earlier projections and likely weighing on sentiment. StreetInsider: PT lowered

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.